VALNEVA The preliminary notice of meeting containing the agenda, the proposed resolutions and instructions for participation and voting was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 25, 2016. Documents and information relating to the meeting are available on Valneva's website (please refer to this link www.valneva.com /en/inves tors-media/agm).
In accordance with applicable law, registered shareholders can, by letter, fax or email, request the Company to provide the meeting documents listed in the French commercial code until the fifth working day before the meeting (please refer to the contact section below).
Holders of bearer shares may exercise this right on condition that they provide a certificate of share ownership issued by an authorized financial institution.
Shareholders may also have access to the documents at the below-mentioned address or the Company's registered office.
ContactsValneva SE,
Legal Department,
6 rue Alain Bombard,
44800 Saint Herblain, France Fax: +33 2 28 07 37 11
Email: assemblée.générale@valneva.com
Laetitia Bachelot-Fontaine Teresa Pinzolits
Head of Investor Relations Corporate Communications Specialist
& Corporate Communications T +43-1-206 20-1116
T +02-28-07-14-19 M +43-676-84 55 67 357
M +33 (0)6 4516 7099communications@valneva.com investors@valneva.com
About Valneva SEValneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine.
The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.
Valneva's portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese Encephalitis (IXIARO®/JESPECT®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66®vaccine production cell line, IC31®adjuvant).
Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland, Canada and Sweden with approximately 400 employees. More information is available atwww.valneva.com.
2/2
Valneva SE published this content on 09 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 09 June 2016 15:54:06 UTC.
Public permalinkhttp://www.publicnow.com/view/58CD64E9F90C2EDA3CB14D565A01F915499FEFD6
